380 related articles for article (PubMed ID: 17909044)
1. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer.
Gan PP; Pasquier E; Kavallaris M
Cancer Res; 2007 Oct; 67(19):9356-63. PubMed ID: 17909044
[TBL] [Abstract][Full Text] [Related]
2. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity.
Gan PP; Kavallaris M
Cancer Res; 2008 Dec; 68(23):9817-24. PubMed ID: 19047161
[TBL] [Abstract][Full Text] [Related]
3. betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer.
McCarroll JA; Gan PP; Liu M; Kavallaris M
Cancer Res; 2010 Jun; 70(12):4995-5003. PubMed ID: 20501838
[TBL] [Abstract][Full Text] [Related]
4. Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression.
Wehbe H; Kearney CM; Pinney KG
Anticancer Res; 2005; 25(6B):3865-70. PubMed ID: 16309172
[TBL] [Abstract][Full Text] [Related]
5. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
6. Microtubule-damaging agents enhance RASSF1A-induced cell death in lung cancer cell lines.
Whang YM; Park KH; Jung HY; Jo UH; Kim YH
Cancer; 2009 Mar; 115(6):1253-66. PubMed ID: 19156899
[TBL] [Abstract][Full Text] [Related]
7. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
8. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
[TBL] [Abstract][Full Text] [Related]
9. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
Sève P; Reiman T; Dumontet C
Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
[TBL] [Abstract][Full Text] [Related]
10. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.
Wang D; Xiang DB; Yang XQ; Chen LS; Li MX; Zhong ZY; Zhang YS
Lung Cancer; 2009 Dec; 66(3):298-304. PubMed ID: 19324449
[TBL] [Abstract][Full Text] [Related]
11. [Class III beta tubulin expression in nonsmall cell lung cancer].
Sève P; Dumontet C
Rev Mal Respir; 2010 Apr; 27(4):383-6. PubMed ID: 20403547
[TBL] [Abstract][Full Text] [Related]
12. [The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs].
Wang JQ; Du ZW; Gao XF; Wu M; Zhang YC; Pan Y; Wang Q; Zhang GZ
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):191-7. PubMed ID: 23856142
[TBL] [Abstract][Full Text] [Related]
13. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel.
Hari M; Yang H; Zeng C; Canizales M; Cabral F
Cell Motil Cytoskeleton; 2003 Sep; 56(1):45-56. PubMed ID: 12905530
[TBL] [Abstract][Full Text] [Related]
14. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin.
Gan PP; McCarroll JA; Po'uha ST; Kamath K; Jordan MA; Kavallaris M
Mol Cancer Ther; 2010 May; 9(5):1339-48. PubMed ID: 20442307
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel and vincristine potentiate adenoviral oncolysis that is associated with cell cycle and apoptosis modulation, whereas they differentially affect the viral life cycle in non-small-cell lung cancer cells.
AbouEl Hassan MA; Braam SR; Kruyt FA
Cancer Gene Ther; 2006 Dec; 13(12):1105-14. PubMed ID: 16841078
[TBL] [Abstract][Full Text] [Related]
16. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
[TBL] [Abstract][Full Text] [Related]
17. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
Ferguson RE; Taylor C; Stanley A; Butler E; Joyce A; Harnden P; Patel PM; Selby PJ; Banks RE
Clin Cancer Res; 2005 May; 11(9):3439-45. PubMed ID: 15867246
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells.
Zhang J; Ren H; Yuan P; Lang W; Zhang L; Mao L
Cancer Res; 2006 Jan; 66(1):18-23. PubMed ID: 16397209
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target.
Fan T; Li R; Todd NW; Qiu Q; Fang HB; Wang H; Shen J; Zhao RY; Caraway NP; Katz RL; Stass SA; Jiang F
Cancer Res; 2007 Aug; 67(16):7901-6. PubMed ID: 17699796
[TBL] [Abstract][Full Text] [Related]
20. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells.
Honore S; Kamath K; Braguer D; Horwitz SB; Wilson L; Briand C; Jordan MA
Cancer Res; 2004 Jul; 64(14):4957-64. PubMed ID: 15256469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
